Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3288026 | 1.00 | FFAR3 (0.36) | FFAR3CYP2C9GRIK1GRIK2KDM4E | |
| SCHEMBL526367 | 1.00 | FFAR3 (0.36) | FFAR3CYP2C9GRIK1GRIK2KDM4E | |
| Hydrochloric Acid SCHEMBL28125142 | 0.98 | FFAR3 (0.35) | FFAR3CYP2C9GRIK1GRIK2KDM4E | |
| Chloromethane SCHEMBL10773493 | 0.95 | FFAR3 (0.33) | FFAR3CYP2C9GRIK1GRIK2TDP1 | |
| Sulfuric Acid SCHEMBL28124682 | 0.91 | FFAR3 (0.31) | FFAR3CYP2C9 | |
| SCHEMBL2417580 | 0.86 | FFAR3 (0.33) | FFAR3CYP2C9 | |
| SCHEMBL20819419 | 0.82 | — | — | |
| SCHEMBL876069 | 0.81 | HDAC3 (0.40) | FFAR3CYP2C9GRIK1GRIK2TSHR | |
| SCHEMBL7636206 | 0.81 | FFAR3 (0.33) | FFAR3GRIK1GRIK2 | |
| SCHEMBL4544359 | 0.80 | TDP1 (0.36) | FFAR3CYP2C9TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2707367-B1 | METHODS FOR PREPARING NAPHTHYRIDINES | BIONOMICS LTD (AU) | 2019-10-09 | — | — | EP | claimed |
| US-20250214998-A1 | CYCLIC COMPOUNDS AS RECEPTOR MODULATING THERAPEUTICS AND METHODS AND USES THEREOF | BIONOMICS LTD (AU) | 2025-07-03 | — | — | US | disclosed |
| US-12275732-B2 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | BIONOMICS LIMITED (AU) | 2025-04-15 | — | — | US | disclosed |
| EP-3867252-B1 | 6-INDAN-2-YLOXY-3-(MORPHOLINE-4-CARBONYL)-1,8-NAPHTHYRIDIN-4-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS MODULATORS OF THE ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR FOR THE TREATMENT OF ANXIETY | BIONOMICS LTD (AU) | 2023-12-06 | — | — | EP | disclosed |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-03-28 | — | — | US | disclosed |
| US-20220409629-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION | PFIZER INC. | 2022-12-29 | — | — | US | disclosed |
| EP-4048665-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION | Reviral Limited (GB) | 2022-08-31 | — | — | EP | disclosed |
| EP-3683220-B1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1-ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF HUNTINGTON'S DISEASE | ASTRAZENECA AB (SE) | 2022-04-13 | — | — | EP | disclosed |
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | BIONOMICS LIMITED (AU) | 2021-11-18 | — | — | US | disclosed |
| US-20020192601-A1 | Process for the production of film having refractive index distribution | MITSUBISHI GAS CHEMICAL COMPANY, INC. | 2002-12-19 | — | — | US | disclosed |
| EP-0882049-B1 | POSSIBLY SUBSTITUTED 8-CYANO-1-CYCLOPROPYL-7-(2,8-DIAZABICYCLO- 4.3.0]-NONAN-8-YL)-6-FLUORO-1,4-DIHYDRO-4-OXO-3-QUINOLIN CARBOXYLIC ACIDS AND THEIR DERIVATIVES | BAYER AG (DE) | 2002-11-20 | — | — | EP | disclosed |
| EP-1255616-A2 | PROCESS FOR THE PRODUCTION OF STRONGLY ADHERENT SURFACE-COATINGS BY PLASMA-ACTIVATED GRAFTING | Ciba SC Holding AG (CH) | 2002-11-13 | — | — | EP | disclosed |
| EP-1215202-A1 | Intermediates for the preparation of possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-(4.3.0)-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives | BAYER AG (DE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001058971-A2 | PROCESS FOR THE PRODUCTION OF STRONGLY ADHERENT SURFACE-COATINGS BY PLASMA-ACTIVATED GRAFTING | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-08-16 | — | — | WO | disclosed |
| EP-0882049-A1 | POSSIBLY SUBSTITUTED 8-CYANO-1-CYCLOPROPYL-7-(2,8-DIAZABICYCLO- 4.3.0]-NONAN-8-YL)-6-FLUORO-1,4-DIHYDRO-4-OXO-3-QUINOLIN CARBOXYLIC ACIDS AND THEIR DERIVATIVES | BAYER AG (DE) | 1998-12-09 | — | — | EP | disclosed |
| EP-0503958-B1 | Heterocyclic compounds and their production | NIPPON PAINT CO LTD (JP) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997031001-A1 | POSSIBLY SUBSTITUTED 8-CYANO-1-CYCLOPROPYL-7-(2,8-DIAZABICYCLO-[4.3.0]-NONAN-8-YL)-6-FLUORO-1,4-DIHYDRO-4-OXO-3-QUINOLIN CARBOXYLIC ACIDS AND THEIR DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-08-28 | — | — | WO | disclosed |
| US-5496943-A | USING UNSATURATED ACYLISOCYANATE COMPOUNDS TO FORM OXAZOLINES, PYRANS WITH AMINOCARBONYLHETERO SUBSTITUTION AND GLUTARIMIDE DERIVATIVES AS CHEMICAL INTERMEDIATES | NIPPON PAINT CO., LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0503958-A2 | Heterocyclic compounds and their production | Nippon Paint Co., Ltd. (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409629-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION | GABRA1, GABRA3, CNR1 | FFAR3 204/4885CYP2C9 525/4885GRIK1 570/4885 |
| US-20250214998-A1 | CYCLIC COMPOUNDS AS RECEPTOR MODULATING THERAPEUTICS AND METHODS AND USES THEREOF | CHRNA7, CHRNA5, CHRNA1 | FFAR3 403/4885CYP2C9 1995/4885GRIK1 87/4885 |
| US-12275732-B2 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | CHRNA7, CHRNA1, CHRNA5 | FFAR3 403/4885CYP2C9 1938/4885GRIK1 89/4885 |
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ATM, BRCA1, CHEK2 | FFAR3 3868/4885CYP2C9 1487/4885GRIK1 3171/4885 |
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | CHRNA7, CHRNA1, CHRNA5 | FFAR3 403/4885CYP2C9 1938/4885GRIK1 89/4885 |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | FFAR3 3868/4885CYP2C9 1487/4885GRIK1 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.